CollPlant Biotechnologies Announces Positive Preclinical Results for Novel Photocurable Regenerative Dermal Filler, Paving Way for Clinical Trials

Reuters

09/30

CollPlant Biotechnologies Announces Positive Preclinical Results for Novel Photocurable Regenerative Dermal Filler, Paving Way for Clinical Trials

CollPlant Biotechnologies Ltd. has announced positive results from non-clinical studies of its photocurable regenerative dermal and soft tissue filler, based on its proprietary non-animal recombinant human collagen (rhCollagen) technology. The comprehensive research program demonstrated long-term durability, biocompatibility, and compliance with international standards, establishing a strong foundation for clinical advancement. These results have not yet been presented publicly but support CollPlant's plans to advance the product candidate into clinical trials. The novel filler combines hyaluronic acid and rhCollagen, offering immediate contouring, structural support, and tissue regeneration in a single treatment, and is expected to set a new standard in aesthetic medicine.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Collplant Biotechnologies Ltd. published the original content used to generate this news brief via PR Newswire (Ref. ID: IO86840) on September 30, 2025, and is solely responsible for the information contained therein.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2571349457"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2571349457\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2571349457?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-09-30 19:00","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2571349457","market":"us","top_or_hot":-1,"title":"CollPlant Biotechnologies Announces Positive Preclinical Results for Novel Photocurable Regenerative Dermal Filler, Paving Way for Clinical Trials","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      CollPlant Biotechnologies Announces Positive Preclinical Results for Novel Photocurable Regenerative Dermal Filler, Paving Way for Clinical Trials\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        CollPlant Biotechnologies Ltd. has announced positive results from non-clinical studies of its photocurable regenerative dermal and soft tissue filler, based on its proprietary non-animal recombinant human collagen (rhCollagen) technology. The comprehensive research program demonstrated long-term durability, biocompatibility, and compliance with international standards, establishing a strong foundation for clinical advancement. These results have not yet been presented publicly but support CollPlant's plans to advance the product candidate into clinical trials. The novel filler combines hyaluronic acid and rhCollagen, offering immediate contouring, structural support, and tissue regeneration in a single treatment, and is expected to set a new standard in aesthetic medicine.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. <a href=\"https://laohu8.com/S/CLGN\">Collplant Biotechnologies</a> Ltd. published the original content used to generate this news brief via PR Newswire (Ref. ID: IO86840) on September 30, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>CollPlant Biotechnologies Announces Positive Preclinical Results for Novel Photocurable Regenerative Dermal Filler, Paving Way for Clinical Trials</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCollPlant Biotechnologies Announces Positive Preclinical Results for Novel Photocurable Regenerative Dermal Filler, Paving Way for Clinical Trials\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-09-30 19:00</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      CollPlant Biotechnologies Announces Positive Preclinical Results for Novel Photocurable Regenerative Dermal Filler, Paving Way for Clinical Trials\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        CollPlant Biotechnologies Ltd. has announced positive results from non-clinical studies of its photocurable regenerative dermal and soft tissue filler, based on its proprietary non-animal recombinant human collagen (rhCollagen) technology. The comprehensive research program demonstrated long-term durability, biocompatibility, and compliance with international standards, establishing a strong foundation for clinical advancement. These results have not yet been presented publicly but support CollPlant's plans to advance the product candidate into clinical trials. The novel filler combines hyaluronic acid and rhCollagen, offering immediate contouring, structural support, and tissue regeneration in a single treatment, and is expected to set a new standard in aesthetic medicine.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. <a href=\"https://laohu8.com/S/CLGN\">Collplant Biotechnologies</a> Ltd. published the original content used to generate this news brief via PR Newswire (Ref. ID: IO86840) on September 30, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250930:nNDL7PjKGv:1","article_id":"2571349457","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2571349457","pubTimestamp":1759230049,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"CollPlant Biotechnologies Announces Positive Preclinical Results for Novel Photocurable Regenerative Dermal Filler, Paving Way for Clinical Trials. CollPlant Biotechnologies Ltd. has announced positive results from non-clinical studies of its photocurable regenerative dermal and soft tissue filler, based on its proprietary non-animal recombinant human collagen  technology. The comprehensive research program demonstrated long-term durability, biocompatibility, and compliance with international standards, establishing a strong foundation for clinical advancement. These results have not yet been presented publicly but support CollPlant's plans to advance the product candidate into clinical trials. The novel filler combines hyaluronic acid and rhCollagen, offering immediate contouring, structural support, and tissue regeneration in a single treatment, and is expected to set a new standard in aesthetic medicine.Disclaimer: This news brief was created by Public Technologies  using generative","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","CLGN":"COLLPLANT BIOTECHNOLOGIES LTD"},"translate_title":"CollPlant Biotechnologies宣布新型光固化再生真皮填充物临床前结果积极，为临床试验铺平道路","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CLGN":0.9},"content_text":"CollPlant Biotechnologies Announces Positive Preclinical Results for Novel Photocurable Regenerative Dermal Filler, Paving Way for Clinical Trials\n    \n\n        CollPlant Biotechnologies Ltd. has announced positive results from non-clinical studies of its photocurable regenerative dermal and soft tissue filler, based on its proprietary non-animal recombinant human collagen (rhCollagen) technology. The comprehensive research program demonstrated long-term durability, biocompatibility, and compliance with international standards, establishing a strong foundation for clinical advancement. These results have not yet been presented publicly but support CollPlant's plans to advance the product candidate into clinical trials. The novel filler combines hyaluronic acid and rhCollagen, offering immediate contouring, structural support, and tissue regeneration in a single treatment, and is expected to set a new standard in aesthetic medicine.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Collplant Biotechnologies Ltd. published the original content used to generate this news brief via PR Newswire (Ref. ID: IO86840) on September 30, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}